And that is what the FDA (and the other authors) suggest they are for;
"Statistical methods are also available to assess stopping for futility; that is, when the likelihood that the treatment effect being sought, based on the interim data, is very unlikely to be established."
From
https://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm127073.pdf
Page 15 Section 4.3.2. Statistical Methods
You write;
So it really says very little about the likely outcome.
At what point do I claim any more than "so the trials continue."
I'm not sure where all the spin is?
Mesoblast has turned a corner, page-380
-
- There are more pages in this discussion • 461 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.02 |
Change
0.015(1.49%) |
Mkt cap ! $1.164B | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.04 | 94.0¢ | $11.76M | 11.90M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 206912 | $1.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 37637 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |